期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
体重调整固定剂量普通肝素与低分子肝素治疗急性静脉血栓栓塞的比较 被引量:1
1
作者 Clive Kearon Jeffrey S. Ginsberg +11 位作者 Jim A. Julian James Douketis Susan Solymoss Paul Ockelford Sharon Jackson Alexander G. Turpie Betsy MacKinnon Jack Hirsh Michael Gent 王春玲(译) 孙艺红(译) 胡大一(校) 《美国医学会杂志(中文版)》 2007年第5期259-264,共6页
背景:普通肝素用于治疗急性静脉血栓栓塞时,通常在监测血凝下静脉输注给药,患者需要住院治疗。然而,体重调整后皮下注射固定剂量普通肝素可能既适用于住院也适用于门诊静脉血栓栓塞患者的治疗。 目的:确定皮下注射体重调整固定剂... 背景:普通肝素用于治疗急性静脉血栓栓塞时,通常在监测血凝下静脉输注给药,患者需要住院治疗。然而,体重调整后皮下注射固定剂量普通肝素可能既适用于住院也适用于门诊静脉血栓栓塞患者的治疗。 目的:确定皮下注射体重调整固定剂量普通肝素治疗静脉血栓栓塞是否与低分子肝素同样安全有效。设计、地点及患者:随机、开标、裁定者盲法、非劣效试验。708例急性静脉血栓栓塞患者来自加拿大和新西兰6所大学附属临床中心,年龄≥18岁。试验于1998年9月至2004年2月进行。在随机分组的患者中,11例从疗效分析中排除,8例从安全性分析中排除。 干预:普通肝素皮下注射初始剂量为333U/kg,以后给予固定剂量250U/kg,每12小时1次(n=345)。低分子肝素(依诺肝素或达肝素)按100IU/kg剂量皮下注射,每12小时1次(n=352)。两种治疗均可院外进行,配合华法林治疗3个月。 主要观测指标:随机分组后3个月内复发性静脉血栓栓塞事件及10天内严重出血情况。结果:普通肝素组有13例患者(3.8%)发生静脉血栓栓塞复发,而低分子肝素组有12例患者复发(3.4%;绝对差值,0.4%;95%可信区间,-2.6%~3.3%)。开始治疗后10天内普通肝素组有4例患者(1.1%)发生严重出血,而低分子肝素组有5例(1.4%;绝对差值,-0.3%;95%可信区间,-2.3%~1.7%)。院外治疗患者在普通肝素组占72%,低分子肝素组占68%。 结论:对于急性静脉血栓栓塞患者而言,皮下注射固定剂量普通肝素与低分子肝素一样安全有效,适于门诊治疗。 展开更多
关键词 低分子肝素治疗 静脉血栓栓塞 普通肝素 固定剂量 急性 体重 安全性分析 皮下注射
下载PDF
体外循环术后追加鱼精蛋白可消除肝素反跳现象吗?
2
作者 Teoh K.H.T. Young E. +1 位作者 Blackall M.H. 丁倩 《世界核心医学期刊文摘(心脏病学分册)》 2005年第1期59-60,共2页
Objectives Heparin rebound, the reappearance of anticoagulant activity after a dequate neutralization with protamine, is thought to contribute to excessive pos toperative bleeding after cardiac surgery. We have previo... Objectives Heparin rebound, the reappearance of anticoagulant activity after a dequate neutralization with protamine, is thought to contribute to excessive pos toperative bleeding after cardiac surgery. We have previously demon-strated tha t a significant amount of heparin is bound nonspecifically to plasma proteins an d is incompletely neutralized by protamine. The aim of this study was to investi gate whether clinically important bleeding attributable to heparin rebound can b e eliminated by infusion of small amounts of additional protamine for 6 hours po stoperatively and whether this treatment can reduce mediastinal blood loss. Meth ods Three hundred patients undergoing elective cardiac surgery were randomized t o receive either a continuous infusion of protamine sulphate(25 mg/h for 6 hours ) postoperatively or saline placebo. Serial blood samples were obtained to measu re thrombin clotting time and anti-factor Xa activity. Heparin bound nonspecifi cally to plasma proteins was measured after displacement with a chemically alter ed heparin with low affinity to antithrombin. Mediastinal blood loss and transfu sion requirements were recorded. Results Heparin rebound was demonstrated in eve ry patient in the placebo group as reflected by increased thrombin clotting time , anti-factor Xa activity, and protein-bound heparin between 1 and 6 hours aft er surgery. In contrast, heparin rebound was eliminated in the protamine infusio n group. The thrombin clotting time was normalized and both heparin concentratio n and protein-bound heparin were almost undetectable (P < .001). There was a mo dest 13%reduction in postoperative bleeding but this did not reduce blood trans fusions. No adverse events were attributable to the extra protamine. Conclusions Postoperative protamine infusion was able to almost totally abolish heparin reb ound. In the context of this study, protamine infusion resulted in reduced posto perative bleeding but the magnitude was insufficient to alter transfusion requir ements. 展开更多
关键词 肝素反跳现象 鱼精蛋白 输血量 凝血时间 安慰剂对照组 蛋白结合 血浆蛋白 抗凝作用 肝素化 特异性
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部